Non-FDA-Approved “off-label” Medication Drugs from the class of atypical antipsychotics like quetiapine are not FDA approved for the management of GAD but are often prescribed as off-label medication in treating psychiatric and behavioral symptoms associated with anxiety among the elderly (Ansara, 2020). However, most clinical guidelines do not recommend the use of this medication as a result of increased mortality rates when used with patients suffering from dementia. However, when is the only available option, then low doses are recommended and titrated upwards based on patients outcome to reduce risks of adverse events. Patients are also advised to monitor associated risks of increased suicidal ideation. Other than that, previous studies have reported great effectiveness, with increased tolerance and adherence level among older adults diagnosed with GAD, with no comorbidities. Nonpharmacological Intervention Cognitive-behavioral therapy (CBT) is recommended as the most effective psychotherapeutic intervention for the management of GAD among the elderly by most national
Order this paper